Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bristol-Myers Squibb Co (BMY) vs Kingsoft Cloud Holdings Limited (KC) Price & Performance

Bristol-Myers Squibb CoTrade
Kingsoft Cloud Holdings LimitedTrade

Price performance (Past 24H)

Key statistics

Bristol-Myers Squibb Co vs Kingsoft Cloud Holdings Limited — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while Kingsoft Cloud Holdings Limited trades at $10.02 (market cap $2.93B). The key difference: Bristol-Myers Squibb Co is far larger — about 39.7× Kingsoft Cloud Holdings Limited's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Kingsoft Cloud Holdings Limited pays none. Which is the better fit depends on your goals.

BMYKC
Market Cap
$116.30B$2.93B
Sector
HealthTechnology
52-Week High
$62.37$18.21
52-Week Low
$42.60$8.58
Enterprise Value
$152.24B$3.23B
Dividend Yield
4.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bristol-Myers Squibb Co

Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.

BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.

Kingsoft Cloud Holdings Limited

Kingsoft Cloud (KC) trades at $10.39, down 4.77% today, with a bullish technical signal and strong analyst support (70% buy ratings). Recent quarters show consistent earnings beats, though the company remains unprofitable with a -9.39% net margin. Revenue growth is robust, driven by AI cloud demand, while cash flow from operations improved to $3.80B in 2025. Technical indicators suggest bullish momentum with support near $10 and resistance at $11.

The stock presents a growth opportunity amid China's AI expansion, but profitability challenges and high valuation multiples pose risks. Analyst consensus points to 25.4% upside potential, though execution on margin improvement is critical for sustained gains. Macroeconomic and regulatory factors in China remain key watchpoints for investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY

About Kingsoft Cloud Holdings Limited

Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.

Read more on KC